The Fight against Poliovirus Is Not Over
Open accessThe DOI matches its Crossref record; 132 of the 137 references it cites were found in a registry or an index; 60 of the 102 sources its claims cite were checked for support.
Abstract
species, and there are three wild PV serotypes: WPV1, WPV2 and WPV3. The launch of the Global Polio Eradication Initiative (GPEI) in 1988 eradicated two of the three serotypes of WPV (WPV2 and WPV3). However, the endemic transmission of WPV1 persists in Afghanistan and Pakistan in 2022. There are cases of paralytic polio due to the loss of viral attenuation in the oral poliovirus vaccine (OPV), known as vaccine-derived poliovirus (VDPV). Between January 2021 and May 2023, a total of 2141 circulating VDPV (cVDPV) cases were reported in 36 countries worldwide. Because of this risk, inactivated poliovirus (IPV) is being used more widely, and attenuated PV2 has been removed from OPV formulations to obtain bivalent OPV (containing only types 1 and 3). In order to avoid the reversion of attenuated OPV strains, the new OPV, which is more stable due to genome-wide modifications, as well as sabin IPV and virus-like particle (VLP) vaccines, is being developed and offers promising solutions for eradicating WP1 and VDPV.
Overview
CoChat Summary
TL;DR
This narrative review summarizes the current epidemiology of wild poliovirus (WPV) and vaccine-derived poliovirus (VDPV) and the vaccine strategies being developed to finish polio eradication. It argues that although WPV2 and WPV3 have been eradicated, WPV1 transmission and cVDPV outbreaks mean the fight against poliovirus is not over.
Key findings
- Two of three WPV serotypes have been eradicated: WPV2 in 2015 and WPV3 in 2019, but endemic WPV1 transmission persisted in Afghanistan and Pakistan in 2022.
- Between January 2021 and May 2023, 2141 cVDPV cases were reported in 36 countries: 269 cVDPV1 cases in 6 countries, 1868 cVDPV2 cases in 35 countries, and 4 cVDPV3 cases in Israel; 1629 were AFP cases and 512 were non-AFP cases, with 1055 environmental samples also positive.
- Reported WPV1 cases included 5 in Afghanistan and Pakistan in 2021 plus 1 in Namibia; in 2022, 2 in Afghanistan, 20 in Pakistan, and 8 in Mozambique; and 1 in Pakistan between January and May 2023.
- New vaccine approaches include nOPV2, with nearly 600 million doses administered in 28 countries, and sIPV mass vaccination in Sichuan, China, which rapidly suppressed cVDPV2 circulation; remdesivir was reported to clear iVDPV from the stool of a 50-year-old patient.
Methods
- Narrative review of poliovirus biology, pathogenesis, diagnosis, vaccines, VDPV emergence, and new eradication strategies.
- Synthesizes published epidemiological reports, WHO/MMWR surveillance data, and clinical trial results; no primary data collection or systematic review methodology is described.
- Main analysis is descriptive and thematic, covering WPV and VDPV epidemiology and candidate vaccines including nOPV2, sIPV, fractional IPV, and virus-like particles.
Limitations
- No explicit limitations section is included; the text notes that eradication remains difficult because of persistent transmission foci and challenges in implementing mass immunization programmes.
- Evident from the text: as a narrative review, it lacks a stated systematic search strategy, inclusion criteria, or quality appraisal, and it relies on cited surveillance reports and trials rather than primary data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
42 Valid · 1 Not valid · 19 Not checked · 6 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A long-standing disadvantage of using OPVs is that attenuated vaccine strains can revert to a neuropathogenic phenotype during their replication in the intestinal tract [9,10,11,12,13,14].”
§ The Fight against Poliovirus Is Not Over > 1. Introduction
What the sources say
- Partly supportedcites [9] Jorba, 2019, Update on Vaccine-Derived Poliovirus Outbreaks-Worldwide, January 2018–June 2019, MMWR Morb. Mortal. Wkly. Rep. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says a novel OPV2 vaccine is designed to reduce the likelihood of reversion to neurovirulence during replication, supporting the core claim about OPV strains. Our copy does not specify that this replication and reversion occur in the intestinal tract. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [10] Blondel, 2008, Evolution génétique du poliovirus: Succès et difficultés de l’éradication de la poliomyélite paralytique [Genetic evolution of poliovirus: Success and difficulties in the eradication of paralytic poliomyelitis], Med. Trop.
- Supportedcites [11] Yeh, 2020, Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence, Cell Host Microbe. source
The Results section, “Characterization of the Shed Viruses” (page unavailable), describes Sabin2 mutations arising during evolution in the human gut and says most vaccinees excrete viruses that have lost an attenuation allele within 14 days. The same section reports that the Sabin2 revertant mutation produced a neurovirulent virus in mice, supporting the stated risk for conventional OPV strains. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [12] Contreras, 1992, Genetic characterization of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract, Biologicals source
- Not checked — no full text of the sourcecites [13] Minor, 2005, Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains, J. Med. Virol. source
- Partly supportedcites [14] Macadam, 2006, Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: Relevance to poliomyelitis eradication, J. Virol. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that polio vaccine viruses can regain virulence through changes acquired during replication, supporting the reversion risk. Our copy does not state that this reversion occurs during replication in the intestinal tract; that specific setting appears only in a reference title. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The oral poliovirus vaccine (OPV) has protected millions of children from paralysis by preventing person-to-person transmission of the virus, which is essential for polio eradication [7].”
§ The Fight against Poliovirus Is Not Over > 1. Introduction
What the sources say
- Partly supportedcites [7] Khan, 2018, Progress Toward Polio Eradication-Worldwide, January 2016–March 2018, MMWR Morb. Mortal. Wkly. Rep. sourceExperimental — accuracy not yet measured
The Discussion (page not specified) says that interrupting poliovirus transmission requires vaccinating missed children and maintaining high population immunity. The Supplementary Immunization Activities section documents extensive OPV use, but the paper does not say that OPV protected millions of children from paralysis or establish that specific outcome through prevention of person-to-person transmission. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“There are cases of paralytic polio due to the loss of viral attenuation in the oral poliovirus vaccine (OPV), known as vaccine-derived poliovirus (VDPV).”
§ The Fight against Poliovirus Is Not Over > Abstract
What the sources say
- Supportedcites [9] Jorba, 2019, Update on Vaccine-Derived Poliovirus Outbreaks-Worldwide, January 2018–June 2019, MMWR Morb. Mortal. Wkly. Rep. source
The paper’s opening section describes OPV as a live, attenuated vaccine and says vaccine-derived strains can cause outbreaks of paralytic poliomyelitis. It also discusses reversion to neurovirulence, supporting the claim’s description of lost attenuation (page not provided in our copy). (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [10] Blondel, 2008, Evolution génétique du poliovirus: Succès et difficultés de l’éradication de la poliomyélite paralytique [Genetic evolution of poliovirus: Success and difficulties in the eradication of paralytic poliomyelitis], Med. Trop.
- Supportedcites [11] Yeh, 2020, Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence, Cell Host Microbe. source
The Results section states that OPV strains can revert to a form that causes paralysis. The Introduction links regained virulence to circulating vaccine-derived polioviruses and reports associated paralytic polio cases. Page numbers are not provided in our copy. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [12] Contreras, 1992, Genetic characterization of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract, Biologicals source
- Not checked — no full text of the sourcecites [13] Minor, 2005, Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains, J. Med. Virol. source
- Supportedcites [14] Macadam, 2006, Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: Relevance to poliomyelitis eradication, J. Virol. source
The Abstract says existing live-attenuated vaccines can revert to virulence and cause disease. It also reports outbreaks of poliomyelitis caused by viruses derived from Sabin vaccine strains, supporting the claim about vaccine-derived poliovirus. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“IPV does not induce sufficient intestinal immunity to be effective in the prevention of virus spread [63,67].”
§ The Fight against Poliovirus Is Not Over > 3. Paralytic Polio Vaccines and Eradication of WPV
What the sources say
- Partly supportedcites [63] Hird, T.R., and Grassly, N.C. (2012). Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog., 8. sourceExperimental — accuracy not yet measured
The Abstract says IPV does not induce enough intestinal mucosal immunity to reduce the prevalence of fecal shedding after oral challenge. But it calls IPV’s effect on transmission in settings with fecal–oral spread unknown, though likely limited compared with OPV. The Discussion also describes reduced transmission in some European settings, so the unqualified claim that IPV is ineffective at preventing virus spread goes beyond the paper. (LLM, conf=0.88)
- Partly supportedcites [67] Mehndiratta, 2014, Poliomyelitis: Historical facts, epidemiology, and current challenges in eradication, Neurohospitalist sourceExperimental — accuracy not yet measured
Table 1 (Introduction; page unavailable) says IPV provides “No gut immunity,” while the Modes of Transmission section says poliovirus spreads through the fecal-oral route. The paper does not explicitly assess whether IPV is ineffective at preventing virus spread, so that part of the claim is not established by our copy. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In March 2022, one case of iVDPV3 was detected in a stool sample from an infant with PID in China [109] (Table 2).”
§ The Fight against Poliovirus Is Not Over > 4. Emergence of Vaccine-Derived Poliovirus Strains
What the sources say
- Supportedcites [109] Yao, 2022, Detection of a Highly Divergent Type 3 Vaccine-Derived Poliovirus in a Child with a Severe Primary Immunodeficiency Disorder-Chongqing, China, 2022, MMWR Morb. Mortal. Wkly. Rep. source
The report’s ‘What is added by this report?’ section states that type 3 vaccine-derived poliovirus was detected in March 2022 in stool specimens from an infant with PID hospitalized in Chongqing, China. The Discussion identifies the infant as an iVDPV patient. (LLM, conf=0.94)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
31 more claims · 17 with their cited sources checked
Create a free account to see all 68 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 6
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Fight against Poliovirus Is Not Over > 4. Emergence of Vaccine-Derived Poliovirus Strains
“suggesting that reversion to the attenuated phenotype of Sabin strains occurs with circulation times of 1–4 years”
§ The Fight against Poliovirus Is Not Over > 1. Introduction
“attenuated vaccine strains can revert to a neuropathogenic phenotype during their replication in the intestinal tract”
Citations
Cites
VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION
Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R., & Pallansch, M. A. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.58.030603.123625 · Cited by 703 · cited 1×
“In communities with low vaccination coverage, these pathogenic OPV-derived strains (known as VDPV, vaccine-derived PV) can have the capacity to circulate in these popula-tions, maintain a reservoir of pathogenic strains and cause polio [15,16].”
BackgroundICTV Virus Taxonomy Profile: Picornaviridae
Zell, R., Delwart, E., Gorbalenya, A. E., Hovi, T., King, A. M. Q., Knowles, N. J., Lindberg, A. M., Pallansch, M. A., Palmenberg, A. C., Reuter, G., et al. (2017) · Journal of General Virology · doi:10.1099/jgv.0.000911 · Cited by 631 · cited 3×
“The genome contains a large open reading frame (ORF), flanked by a highly structured 5′ untranslated region (5′ UTR) and a 3′ UTR terminated with a poly(A) tail [17].”
BackgroundInfluentialKew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., et al. (2002) · Science · doi:10.1126/science.1068284 · Cited by 600 · cited 1×
“Affected patients were either partially vaccinated or unvaccinated [91].”
BackgroundThe life cycle of non-polio enteroviruses and how to target it
Baggen, J., Thibaut, H. J., Strating, J. R. P. M., & van Kuppeveld, F. J. M. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0005-4 · Cited by 478
From Emergence to Eradication: The Epidemiology of Poliomyelitis Deconstructed
Nathanson, N., & Kew, O. M. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwq320 · Cited by 404 · cited 8×
“Less than 1% of polio cases result in temporary or permanent acute flaccid paralysis (AFP) [22].”
BackgroundInfluentialOne hundred years of poliovirus pathogenesis
Racaniello, V. R. (2006) · Virology · doi:10.1016/j.virol.2005.09.015 · Cited by 322 · cited 1×
“PV has a limited host range, and humans are the only natural reservoir [20,21].”
BackgroundBurns, C. C., Diop, O. M., Sutter, R. W., & Kew, O. M. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu295 · Cited by 309
Polio vaccination: Past, present and future
Bandyopadhyay, A. S., Garon, J., Seib, K., & Orenstein, W. A. (2015) · Future Microbiology · doi:10.2217/fmb.15.19 · Cited by 276 · cited 1×
“OPV confers passive immunity to unvaccinated individuals through the attenuated vaccine strains shed in the feces of vaccinated individuals [65].”
BackgroundEmerging Concept of Poliomyelitis Infection
Bodian, D. (1955) · Science · doi:10.1126/science.122.3159.105 · Cited by 251 · cited 1×
“After infection, the virus first replicates in the pharynx and small intestine, particularly in the lymphoid tissues (tonsils and Peyer’s patches) [26].”
BackgroundMucosal Immunity Induced by Enhanced-Potency Inactivated and Oral Polio Vaccines
Onorato, I. M., Modlin, J. F., McBean, A. M., Thoms, M. L., Losonsky, G. A., & Bernier, R. H. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.1.1 · Cited by 246
Brown, B., Oberste, M. S., Maher, K., & Pallansch, M. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8973-8984.2003 · Cited by 238 · cited 2×
“PV is classified within the Enterovirus C species, and there are three wild PV serotypes: WPV1, WPV2 and WPV3 [1].”
BackgroundPathogenesis of Poliomyelitis Reappraisal in the Light of New Data
Sabin, A. B. (1956) · Science · doi:10.1126/science.123.3209.1151 · Cited by 236 · cited 1×
“PV then migrates to the regional lymph nodes (cervical and mesenteric) and into the bloodstream [27].”
BackgroundParalytic poliomyelitis: Seasoned strategies, disappearing disease
Hull, H. F., Ward, N. A., Hull, B. P., Milstien, J. B., Hull, H. F., & de Quadros, C. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92472-4 · Cited by 235 · cited 1×
“This means that approximately 1000 people were newly paralyzed, and between 50 and 100 people died of the disease every day worldwide [60,61].”
BackgroundCirculation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993
Yang, C.-F., Naguib, T., Yang, S.-J., Nasr, E., Jorba, J., Ahmed, N., Campagnoli, R., van der Avoort, H., Shimizu, H., Yoneyama, T., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.15.8366-8377.2003 · Cited by 233
Hird, T. R., & Grassly, N. C. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002599 · Cited by 221 · cited 3×
“The two types of vaccine used against the disease, injectable inactivated polio vaccine (IPV) and oral polio vaccine (OPV), have played a crucial role in reducing the number of cases [61,63].”
BackgroundNorton, E. B., Lawson, L. B., Freytag, L. C., & Clements, J. D. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00538-10 · Cited by 221
Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence
Yeh, M. T., Bujaki, E., Dolan, P. T., Smith, M., Wahid, R., Konz, J., Weiner, A. J., Bandyopadhyay, A. S., Van Damme, P., De Coster, I., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.003 · Cited by 221 · cited 3×
“Similarly, nOPV2-c2 has the same genetically stabilised V region and a capsid coding region optimised at the codon level [11].”
BackgroundProlonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient
Kew, O. M., Sutter, R. W., Nottay, B. K., McDonough, M. J., Prevots, D. R., Quick, L., & Pallansch, M. A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2893-2899.1998 · Cited by 213 · cited 1×
“These individuals may represent a potential source of virus reintroduction once the disease is eradicated [107,108].”
BackgroundUpdate on Vaccine-Derived Polioviruses-Worldwide, January 2017–June 2018
Jorba, J., Diop, O. M., Iber, J., Henderson, E., Zhao, K., Sutter, R. W., Wassilak, S. G. F., & Burns, C. C. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6742a5 · Cited by 197 · cited 1×
“These were primarily isolated from environmental specimens [110] (Table 2).”
BackgroundKilpatrick, D. R., Yang, C.-F., Ching, K., Vincent, A., Iber, J., Campagnoli, R., Mandelbaum, M., De, L., Yang, S.-J., Nix, A., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00702-09 · Cited by 187 · cited 1×
“This is known as intra-typical differentiation (ITD) [42,43,47,48].”
BackgroundThe Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT
Clements, J. D., & Norton, E. B. (2018) · mSphere · doi:10.1128/msphere.00215-18 · Cited by 177
Insidious reintroduction of wild poliovirus into Israel, 2013
Anis, E., Kopel, E., Singer, S. R., Kaliner, E., Moerman, L., Moran-Gilad, J., Sofer, D., Manor, Y., Shulman, L. M., Mendelson, E., et al. (2013) · Eurosurveillance · doi:10.2807/1560-7917.es2013.18.38.20586 · Cited by 162
Balanant, J., Guillot, S., Candrea, A., Delpeyroux, F., & Crainic, R. (1991) · Virology · doi:10.1016/0042-6822(91)90434-d · Cited by 160
Burns, C. C., Shaw, J., Jorba, J., Bukbuk, D., Adu, F., Gumede, N., Pate, M. A., Abanida, E. A., Gasasira, A., Iber, J., et al. (2013) · Journal of Virology · doi:10.1128/jvi.02954-12 · Cited by 153 · cited 1×
“Among the different categories of VDPVs, cVDPVs are currently the greatest public health concern [87,88].”
BackgroundNeutralization of poliovirus by cell receptors expressed in insect cells
Kaplan, G., Freistadt, M. S., & Racaniello, V. R. (1990) · Journal of Virology · doi:10.1128/jvi.64.10.4697-4702.1990 · Cited by 151 · cited 1×
“This process is known as decapsidation [24,25].”
Herremans, T. M. P. T., Reimerink, J. H. J., Buisman, A. M., Kimman, T. G., & Koopmans, M. P. G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.5011 · Cited by 149
Circulation of type 1 vaccine-derived poliovirus in the philippines in 2001
Shimizu, H., Thorley, B., Paladin, F. J., Brussen, K. A., Stambos, V., Yuen, L., Utama, A., Tano, Y., Arita, M., Yoshida, H., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.24.13512-13521.2004 · Cited by 146
An upstream protein-coding region in enteroviruses modulates virus infection in gut epithelial cells
Lulla, V., Dinan, A. M., Hosmillo, M., Chaudhry, Y., Sherry, L., Irigoyen, N., Nayak, K. M., Stonehouse, N. J., Zilbauer, M., Goodfellow, I., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0297-1 · Cited by 146 · cited 1×
“A second, shorter ORF (ORF2) translated into a single protein (ORF2p) was recently identified in human EVs [18,19].”
BackgroundSutter, R. W., John, T. J., Jain, H., Agarkhedkar, S., Ramanan, P. V., Verma, H., Deshpande, J. M., Singh, A. P., Sreevatsava, M., Malankar, P., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61230-5 · Cited by 144 · cited 4×
“There are three OPV formulations, each containing different combinations of Sabin PV strains for the three serotypes: tOPV (trivalent OPV), bOPV (bivalent OPV) and mOPV (monovalent OPV). tOPV, used for routine polio immunisation and mass campaigns in over 100 countries, has been gradually replaced by bOPV types 1 and…”
BackgroundInfluentialMehndiratta (2014) · doi:10.1177/1941874414533352 · Cited by 141 · cited 2×
“IPV does not induce sufficient intestinal immunity to be effective in the prevention of virus spread [63,67].”
BackgroundRecombinant Vaccine–Derived Poliovirus in Madagascar
Rousset, D., Rakoto-Andrianarivelo, M., Razafindratsimandresy, R., Randriamanalina, B., Guillot, S., Balanant, J., Mauclère, P., & Delpeyroux, F. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0907.020692 · Cited by 138
Combelas, N., Holmblat, B., Joffret, M.-L., Colbère-Garapin, F., & Delpeyroux, F. (2011) · Viruses · doi:10.3390/v3081460 · Cited by 135 · cited 1×
“For example, recombinant cVDPV2 was involved in the polio outbreaks in India and the Democratic Republic of Congo between 2008 and 2010 [103].”
BackgroundInactivated poliovirus vaccine: Past and present experience
Murdin, A. D., Barreto, L., & Plotkin, S. (1996) · Vaccine · doi:10.1016/0264-410x(95)00211-i · Cited by 135 · cited 1×
“The high standards of hygiene and sanitation in these countries may explain this eradication [73].”
BackgroundPoliovirus and poliomyelitis: A tale of guts, brains, and an accidental event
Mueller, S., Wimmer, E., & Cello, J. (2005) · Virus Research · doi:10.1016/j.virusres.2005.04.008 · Cited by 133 · cited 1×
“PV has a limited host range, and humans are the only natural reservoir [20,21].”
BackgroundImplications of a circulating vaccine-derived poliovirus in Nigeria
Jenkins, H. E., Aylward, R. B., Gasasira, A., Donnelly, C. A., Mwanza, M., Corander, J., Garnier, S., Chauvin, C., Abanida, E., Pate, M. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0910074 · Cited by 131
The Evolutionary Pathway to Virulence of an RNA Virus
Stern, A., Yeh, M. T., Zinger, T., Smith, M., Wright, C., Ling, G., Nielsen, R., Macadam, A., & Andino, R. (2017) · Cell · doi:10.1016/j.cell.2017.03.013 · Cited by 127 · cited 1×
“A number of studies have identified three specific codon positions that are involved in this reversion, two in the 5′ UTR region and one in the VP1 region [82,83].”
BackgroundComparative study of five methods for intratypic differentiation of polioviruses
van der Avoort, H. G., Hull, B. P., Hovi, T., Pallansch, M. A., Kew, O. M., Crainic, R., Wood, D. J., Mulders, M. N., & van Loon, A. M. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.10.2562-2566.1995 · Cited by 122
Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine
Marsian, J., Fox, H., Bahar, M. W., Kotecha, A., Fry, E. E., Stuart, D. I., Macadam, A. J., Rowlands, D. J., & Lomonossoff, G. P. (2017) · Nature Communications · doi:10.1038/s41467-017-00090-w · Cited by 121
Wassilak, S., Pate, M. A., Wannemuehler, K., Jenks, J., Burns, C., Chenoweth, P., Abanida, E. A., Adu, F., Baba, M., Gasasira, A., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq140 · Cited by 120 · cited 1×
“Strikingly, the cVDPVs involved in most of the above epidemics were recombinant strains, the product of genetic exchange between OPV strains and other Enterovirus C [97,101,102].”
BackgroundIntrathecal Immune Response in Patients with the Post-Polio Syndrome
Sharief, M. K., Hentges, R., & Ciardi, M. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109123251101 · Cited by 119 · cited 1×
“Indeed, inflammatory changes in the spinal cord have been observed postmortem in PPS patients [38,39].”
BackgroundPost-polio Syndrome: More Than Just a Lower Motor Neuron Disease
Li Hi Shing, S., Chipika, R. H., Finegan, E., Murray, D., Hardiman, O., & Bede, P. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00773 · Cited by 115
Efficacy of inactivated poliovirus vaccine in India
Jafari, H., Deshpande, J. M., Sutter, R. W., Bahl, S., Verma, H., Ahmad, M., Kunwar, A., Vishwakarma, R., Agarwal, A., Jain, S., et al. (2014) · Science · doi:10.1126/science.1255006 · Cited by 112 · cited 1×
“The results showed that in children who had previously been vaccinated with OPV, the administration of IPV significantly reduced the proportion of subjects who shed virus after a first dose of OPV [75,76].”
BackgroundHummeler, K., Anderson, T. F., & Brown, R. A. (1962) · Virology · doi:10.1016/0042-6822(62)90205-2 · Cited by 111
John, J., Giri, S., Karthikeyan, A. S., Iturriza-Gomara, M., Muliyil, J., Abraham, A., Grassly, N. C., & Kang, G. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60934-x · Cited by 109 · cited 1×
“The results showed that in children who had previously been vaccinated with OPV, the administration of IPV significantly reduced the proportion of subjects who shed virus after a first dose of OPV [75,76].”
BackgroundStrebel, P. M., Ion-Nedelcu, N., Baughman, A. L., Sutter, R. W., & Cochi, S. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502233320804 · Cited by 105 · cited 1×
“It has been reported that multiple intramuscular injections administered during the incubation period of WPV infection or shortly after exposure to OPV increase the risk of paralytic poliomyelitis [33,34].”
BackgroundSaletti, G., Çuburu, N., Yang, J. S., Dey, A., & Czerkinsky, C. C. (2013) · Nature Protocols · doi:10.1038/nprot.2013.058 · Cited by 102 · cited 1×
“The detection of ASCs in the blood as early as 5 days after vaccination or natural infection indicates recent exposure [56].”
BackgroundHenry, J. L., Jaikaran, E. S., Davies, J. R., Tomlinson, A. J. H., Mason, P. J., Barnes, J. M., & Beale, A. J. (1966) · Journal of Hygiene · doi:10.1017/s0022172400040389 · Cited by 101 · cited 1×
“However, this reduction is much less than the reduction seen in people who have received OPV [71,72].”
BackgroundReemergence of recombinant vaccine–derived poliovirus outbreak in Madagascar.
Rakoto‐Andrianarivelo, M., Gumede, N., Jegouic, S., Balanant, J., Andriamamonjy, S. N., Rabemanantsoa, S., Birmingham, M., Randriamanalina, B., Nkolomoni, L., Venter, M., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/587694 · Cited by 100
Complexes of poliovirus serotypes with their common cellular receptor, CD155
He, Y., Mueller, S., Chipman, P. R., Bator, C. M., Peng, X., Bowman, V. D., Mukhopadhyay, S., Wimmer, E., Kuhn, R. J., & Rossmann, M. G. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4827-4835.2003 · Cited by 98 · cited 1×
“All three PV serotypes infect host cells by binding to a common cellular receptor called CD155 (or PV receptor, previously abbreviated PVR) [23].”
BackgroundUrakawa, T., Ferguson, M., Minor, P. D., Cooper, J., Sullivan, M., Almond, J. W., & Bishop, D. H. L. (1989) · Journal of General Virology · doi:10.1099/0022-1317-70-6-1453 · Cited by 97
Chapter 1 The Pathogenesis of Poliomyelitis: What We Don't Know
Nathanson, N. (2008) · Advances in Virus Research · doi:10.1016/s0065-3527(08)00001-8 · Cited by 95 · cited 2×
“In the CNS, PV can destroy motor neurons in the anterior corona of the spinal cord, causing a characteristic flaccid paralysis without permanent sensory loss (Figure 1) [4].”
BackgroundArita, M., Zhu, S.-L., Yoshida, H., Yoneyama, T., Miyamura, T., & Shimizu, H. (2005) · Journal of Virology · doi:10.1128/jvi.79.20.12650-12657.2005 · Cited by 95
Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa054960 · Cited by 90 · cited 1×
“Several studies have shown that IPV reduces the duration and rate of virus shedding in immunised individuals compared with unimmunised individuals, although IPV is not effective in preventing PV replication in the gut [69,70].”
BackgroundMacadam, A. J., Ferguson, G., Stone, D. M., Meredith, J., Knowlson, S., Auda, G., Almond, J. W., & Minor, P. D. (2006) · Journal of Virology · doi:10.1128/jvi.00370-06 · Cited by 89
Vaccine-Derived Poliomyelitis 12 Years after Infection in Minnesota
DeVries, A. S., Harper, J., Murray, A., Lexau, C., Bahta, L., Christensen, J., Cebelinski, E., Fuller, S., Kline, S., Wallace, G. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008677 · Cited by 88
Serial Recombination during Circulation of Type 1 Wild-Vaccine Recombinant Polioviruses in China
Liu, H.-M., Zheng, D.-P., Zhang, L.-B., Oberste, M. S., Kew, O. M., & Pallansch, M. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.10994-11005.2003 · Cited by 88 · cited 1×
“This instability is caused by the lack of a corrective function in RNA-dependent RNA polymerase, leading to point mutations occurring [83,84].”
BackgroundDe Coster, I., Leroux-Roels, I., Bandyopadhyay, A. S., Gast, C., Withanage, K., Steenackers, K., De Smedt, P., Aerssens, A., Leroux-Roels, G., Oberste, M. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32541-1 · Cited by 86
Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains
Laassri, M., Lottenbach, K., Belshe, R., Wolff, M., Rennels, M., Plotkin, S., & Chumakov, K. (2005) · The Journal of Infectious Diseases · doi:10.1086/498172 · Cited by 85 · cited 1×
“Several studies have shown that IPV reduces the duration and rate of virus shedding in immunised individuals compared with unimmunised individuals, although IPV is not effective in preventing PV replication in the gut [69,70].”
BackgroundUpdate on Vaccine-Derived Poliovirus Outbreaks-Worldwide, January 2018–June 2019
Jorba, J., Diop, O. M., Iber, J., Henderson, E., Zhao, K., Quddus, A., Sutter, R., Vertefeuille, J. F., Wenger, J., Wassilak, S. G. F., et al. (2019) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6845a4 · Cited by 83
Sáez-Llorens, X., Bandyopadhyay, A. S., Gast, C., Leon, T. D., DeAntonio, R., Jimeno, J., Caballero, M. I., Aguirre, G., Oberste, M. S., Weldon, W. C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32540-x · Cited by 81
Guo, H., Li, Y., Liu, G., Jiang, Y., Shen, S., Bi, R., Huang, H., Cheng, T., Wang, C., & Wei, W. (2019) · Nature Communications · doi:10.1038/s41467-019-12040-9 · Cited by 80 · cited 1×
“A second, shorter ORF (ORF2) translated into a single protein (ORF2p) was recently identified in human EVs [18,19].”
BackgroundA Large Vaccine‐Derived Poliovirus Outbreak on Madura Island—Indonesia, 2005
Estívariz, C. F., Watkins, M. A., Handoko, D., Rusipah, R., Deshpande, J., Rana, B. J., Irawan, E., Widhiastuti, D., Pallansch, M. A., Thapa, A., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/525049 · Cited by 77
Postpolio syndrome: poliovirus persistence is involved in the pathogenesis
Julien, J., Leparc-Goffart, I., Lina, B., Fuchs, F., Foray, S., Malcová, I., Aymard, M., & Kopecká, H. (1999) · Journal of Neurology · doi:10.1007/s004150050386 · Cited by 76 · cited 7×
“Almost half of acute polio survivors develop post-polio syndrome (PPS) [35], which is the late onset or worsening of new disabling neuromuscular symptoms 30–40 years after initial polio [35].”
BackgroundResultInfluentialNorton, E. B., Bauer, D. L., Weldon, W. C., Oberste, M. S., Lawson, L. B., & Clements, J. D. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.02.069 · Cited by 76
Parker, E. P. K., Molodecky, N. A., Pons-Salort, M., O’Reilly, K. M., & Grassly, N. C. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1052800 · Cited by 75 · cited 2×
“The presence of antibodies at a dilution of at least 1:8 is considered a reliable indicator of protection [52,53].”
BackgroundCharacterization of poliovirus conformational alteration mediated by soluble cell receptors
Yafal, A. G., Kaplan, G., Racaniello, V. R., & Hogle, J. M. (1993) · Virology · doi:10.1006/viro.1993.1621 · Cited by 75
Prior poliomyelitis-evidence of cytokine production in the central nervous system
Gonzalez, H., Khademi, M., Andersson, M., et al. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00316-7 · Cited by 74 · cited 1×
“In addition, levels of TNF-α and IFN-γ have been observed in the serum and cerebrospinal fluid of PPS patients [40,41].”
BackgroundMolecular Mechanisms of Poliovirus Variation and Evolution
Agol, V. I. (2006) · Current Topics in Microbiology and Immunology · doi:10.1007/3-540-26397-7_8 · Cited by 73 · cited 1×
“Due to the variability and rapid evolution of enteroviruses, polio eradication may be more difficult than initially expected [8].”
BackgroundNucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis
Buttinelli, G., Donati, V., Fiore, S., Marturano, J., Plebani, A., Balestri, P., Soresina, A. R., Vivarelli, R., Delpeyroux, F., Martin, J., et al. (2003) · Journal of General Virology · doi:10.1099/vir.0.18974-0 · Cited by 73 · cited 1×
“These individuals may represent a potential source of virus reintroduction once the disease is eradicated [107,108].”
BackgroundBräutigam, S., Snezhkov, E., & Bishop, D. H. L. (1993) · Virology · doi:10.1006/viro.1993.1067 · Cited by 72
THE INCUBATION PERIOD IN HUMAN POLIOMYELITIS AND ITS IMPLICATIONS
Horstmann, D. M., & PAUL, J. R. (1947) · JAMA · doi:10.1001/jama.1947.02890010013004 · Cited by 72 · cited 1×
“The average incubation period for poliomyelitis is approximately 10 days (range 5–25 days) [30,31].”
BackgroundDiagnostic Assay Development for Poliovirus Eradication
Gerloff, N., Sun, H., Mandelbaum, M., Maher, C., Nix, W. A., Zaidi, S., Shaukat, S., Seakamela, L., Nalavade, U. P., Sharma, D. K., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01624-17 · Cited by 72 · cited 2×
“This is known as intra-typical differentiation (ITD) [42,43,47,48].”
BackgroundMethodPoliovirus Receptor on Human Blood Cells: A Possible Extraneural Site of Poliovirus Replication
Freistadt, M. S., Fleit, H. B., & Wimmer, E. (1993) · Virology · doi:10.1006/viro.1993.1433 · Cited by 70 · cited 1×
“In some cases, the virus can reach the CNS by crossing the blood–brain barrier via infected mononuclear cells [28].”
BackgroundIsolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child
Adu, F., Iber, J. C., Bukbuk, D. N., Gumede, N., Yang, S.-J., Jorba, J. C., Campagnoli, R. P., Sule, W. F., Yang, C.-F., Burns, C. C., et al. (2007) · Virus Research · doi:10.1016/j.virusres.2007.03.009 · Cited by 70
Increasing Type 1 Poliovirus Capsid Stability by Thermal Selection
Adeyemi, O. O., Nicol, C., Stonehouse, N. J., & Rowlands, D. J. (2016) · Journal of Virology · doi:10.1128/jvi.01586-16 · Cited by 67
Poliovirus vaccination options for achieving eradication and securing the endgame
Estívariz, C. F., Pallansch, M. A., Anand, A., Wassilak, S. G., Sutter, R. W., Wenger, J. D., & Orenstein, W. A. (2013) · Current Opinion in Virology · doi:10.1016/j.coviro.2013.05.007 · Cited by 66
Progress Toward Polio Eradication-Worldwide, January 2016–March 2018
Khan, F., Datta, S. D., Quddus, A., Vertefeuille, J. F., Burns, C. C., Jorba, J., & Wassilak, S. G. F. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6718a4 · Cited by 66
Ansardi, D. C., Porter, D. C., & Morrow, C. D. (1991) · Journal of Virology · doi:10.1128/jvi.65.4.2088-2092.1991 · Cited by 64
Li, L., Ivanova, O., Driss, N., Tiongco-Recto, M., da Silva, R., Shahmahmoodi, S., Sazzad, H. M. S., Mach, O., Kahn, A.-L., & Sutter, R. W. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu065 · Cited by 63 · cited 1×
“Immunocompetent individuals clear attenuated vaccine virus from their bodies after a limited period of shedding, unlike immunocompromised individuals, who may be unable to clear the intestinal replication of the vaccine virus, resulting in persistent intestinal poliovirus infection and prolonged shedding [105,106].”
BackgroundOkayasu, H., Sein, C., Chang Blanc, D., Gonzalez, A. R., Zehrung, D., Jarrahian, C., Macklin, G., & Sutter, R. W. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix038 · Cited by 62
Progress Toward Polio Eradication-Worldwide, January 2020–April 2022
Rachlin, A., Patel, J. C., Burns, C. C., Jorba, J., Tallis, G., O’Leary, A., Wassilak, S. G. F., & Vertefeuille, J. F. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7119a2 · Cited by 61 · cited 10×
“To date, among the three serotypes of WPV, only WPV1 remains endemic in two countries in the world, Pakistan and Afghanistan [5].”
BackgroundInfluentialEVALUATION OF RED CROSS GAMMA GLOBULIN AS A PROPHYLACTIC AGENT FOR POLIOMYELITIS
Hammon, W. M. (1954) · JAMA · doi:10.1001/jama.1954.02950010023009 · Cited by 56
White, J. A., Blum, J. S., Hosken, N. A., Marshak, J. O., Duncan, L., Zhu, C., Norton, E. B., Clements, J. D., Koelle, D. M., Chen, D., et al. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.32253 · Cited by 51
Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication
Modlin, J. F., Bandyopadhyay, A. S., & Sutter, R. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa622 · Cited by 49 · cited 1×
“This vaccine contains an alum adjuvant and has only one-tenth of the antigen content of the conventional IPV [112].”
BackgroundMacklin, G., Liao, Y., Takane, M., Dooling, K., Gilmour, S., Mach, O., Kew, O. M., Sutter, R. W., & The iVDPV Working Group (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01103 · Cited by 47 · cited 3×
“Since 2000, the number of reported cases has increased, particularly in low- and middle-income countries, while the number of reported cases has decreased in high-income countries [106].”
BackgroundSutter, R. W., Patriarca, P. A., Suleiman, A. J. M., Brogan, S., Malankar, P. G., Cochi, S. L., Al-Ghassani, A. A. K., & El-Bualy, M. S. (1992) · Journal of Infectious Diseases · doi:10.1093/infdis/165.3.444 · Cited by 46 · cited 1×
“It has been reported that multiple intramuscular injections administered during the incubation period of WPV infection or shortly after exposure to OPV increase the risk of paralytic poliomyelitis [33,34].”
BackgroundMacklin, G., Diop, O. M., Humayun, A., Shahmahmoodi, S., El-Sayed, Z. A., Triki, H., Rey, G., Avagyan, T., Grabovac, V., Jorba, J., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6928a4 · Cited by 46 · cited 1×
“From July 2018 to December 2019, 16 new iVDPV cases were reported in Argentina, Egypt, Iran, Philippines and Tunisia, including 8 iVDPV1, 7 iVDPV3 and 1 iVDPV2 [86] (Table 2).”
BackgroundPoliomyelitis is a current challenge: long-term sequelae and circulating vaccine-derived poliovirus
Quarleri, J. F. (2022) · GeroScience · doi:10.1007/s11357-022-00672-7 · Cited by 46 · cited 1×
“PV strains with reduced neurovirulence were developed using an attenuation technique of successive passages of the virus in non-human primates and in cultured primate cells [64].”
MethodSequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis
Ciapponi, A., Bardach, A., Ares, L. R., Glujovsky, D., Cafferata, M. L., Cesaroni, S., & Aikant, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011260.pub2 · Cited by 45 · cited 1×
“The OPV has been essential in eradicating wild-derived poliomyelitis worldwide by inducing high intestinal immunity to prevent human-to-human transmission of poliovirus in communities [77].”
BackgroundIdentification of vaccine-derived polioviruses using dual-stage real-time RT-PCR
Kilpatrick, D. R., Ching, K., Iber, J., Chen, Q., Yang, S.-J., De, L., Williams, A. J., Mandelbaum, M., Sun, H., Oberste, M. S., et al. (2014) · Journal of Virological Methods · doi:10.1016/j.jviromet.2013.11.017 · Cited by 45 · cited 1×
“This is known as intra-typical differentiation (ITD) [42,43,47,48].”
BackgroundThe Incubation Period of Poliomyelitis
Sartwell, P. E. (1952) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.42.11.1403 · Cited by 44 · cited 1×
“The average incubation period for poliomyelitis is approximately 10 days (range 5–25 days) [30,31].”
BackgroundThe case for global eradication of poliomyelitis.
(1987) · Europe PMC (PubMed Central) · Cited by 43
Zhaori, G., Sun, M., Faden, H. S., & Ogra, P. L. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.6.1018 · Cited by 42 · cited 1×
“Tests include ELISA for PV-specific IgA and neutralisation tests [55].”
MethodBahar, M. W., Porta, C., Fox, H., Macadam, A. J., Fry, E. E., & Stuart, D. I. (2021) · npj Vaccines · doi:10.1038/s41541-020-00267-3 · Cited by 42
Bernstein, D. I., Pasetti, M. F., Brady, R. C., Buskirk, A. D., Wahid, R., Dickey, M., Cohen, M. B., Baughman, H., El-Khorazaty, J. A., Maier, N., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.12.011 · Cited by 41
Xu, W., & Zhang, Y. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3292-4_10 · Cited by 40 · cited 1×
“Therefore, L20B (a mouse L cell line expressing the PV receptor) is currently preferred because it is more sensitive and selective for detecting PV [42,45,46].”
BackgroundZaman, K., Bandyopadhyay, A. S., Hoque, M., Gast, C., Yunus, M., Jamil, K. M., Mainou, B. A., Konopka-Anstadt, J. L., Hendley, W. S., Vincent, A., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02397-2 · Cited by 39
Lee, T., Gutiérrez, R. L., Maciel, M., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.032 · Cited by 35
Xu, Y., Ma, S., Huang, Y., Chen, F., Chen, L., Ding, D., Zheng, Y., Li, H., Xiao, J., Feng, J., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.03.031 · Cited by 34
The role of genetic sequencing and analysis in the polio eradication programme
Jorgensen, D., Pons-Salort, M., Shaw, A. G., & Grassly, N. C. (2020) · Virus Evolution · doi:10.1093/ve/veaa040 · Cited by 31 · cited 3×
“This instability is caused by the lack of a corrective function in RNA-dependent RNA polymerase, leading to point mutations occurring [83,84].”
BackgroundSurveillance to Track Progress Toward Polio Eradication-Worldwide, 2019–2020
Tuma, J. N., Wilkinson, A. L., Diop, O. M., Jorba, J., Gardner, T., Snider, C. J., Anand, A., & Ahmed, J. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7018a2 · Cited by 30
Mirzoev, A., Macklin, G. R., Zhang, Y., Mainou, B. A., Sadykova, U., Olsavszky, V. S., Huseynov, S., Ruziev, M., Saidzoda, F., Bobokhonova, M., et al. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00412-0 · Cited by 30
Dey, A., Molodecky, N. A., Verma, H., Sharma, P., Yang, J. S., Saletti, G., Ahmad, M., Bahl, S. K., Wierzba, T. F., Nandy, R. K., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146010 · Cited by 29
Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis
Viktorova, E. G., Khattar, S. K., Kouiavskaia, D., Laassri, M., Zagorodnyaya, T., Dragunsky, E., Samal, S., Chumakov, K., & Belov, G. A. (2018) · Journal of Virology · doi:10.1128/jvi.00976-18 · Cited by 29
Sutter (2000) · doi:10.1016/s0031-3955(05)70208-x · Cited by 28
Minor, P. D., Dunn, G., Ramsay, M. E., & Brown, D. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20250 · Cited by 28
Contreras, G., Dimock, K., Furesz, J., Gardell, C., Hazlett, D., Karpinski, K., McCorkle, G., & Wu, L. (1992) · Biologicals · doi:10.1016/s1045-1056(05)80003-x · Cited by 27
Arita, M., Ling, H., Yan, D., Nishimura, Y., Yoshida, H., Wakita, T., & Shimizu, H. (2009) · BMC Infectious Diseases · doi:10.1186/1471-2334-9-208 · Cited by 26
Culture-Independent Detection of Poliovirus in Stool Samples by Direct RNA Extraction
Harrington, C., Sun, H., Jeffries-Miles, S., Gerloff, N., Mandelbaum, M., Pang, H., Collins, N., Burns, C. C., & Vega, E. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00668-21 · Cited by 25
Svennerholm, A., Qadri, F., Lundgren, A., Kaim, J., Bhuiyan, T. R., Akhtar, M., Maier, N., Bourgeois, A. L., & Walker, R. I. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.056 · Cited by 25
Post-poliomyelitis Syndrome: Case Report and Review of the Literature
Lin, K., & Lim, Y. (2005) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v34n7p447 · Cited by 23
Korotkova, E. A., Gmyl, A. P., Yakovenko, M. L., Ivanova, O. E., Eremeeva, T. P., Kozlovskaya, L. I., Shakaryan, A. K., Lipskaya, G. Y., Parshina, I. L., Loginovskikh, N. V., et al. (2016) · Journal of Virology · doi:10.1128/jvi.00277-16 · Cited by 23
Progress toward poliomyelitis eradication - Nigeria, January 2009-June 2010.
(2010) · PubMed · Cited by 22
Crothers, J. W., Ross Colgate, E., Cowan, K. J., Dickson, D. M., Walsh, M., Carmolli, M., Wright, P. F., Norton, E. B., & Kirkpatrick, B. D. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.056 · Cited by 18
Production and characterisation of stabilised PV-3 virus-like particles using Pichia pastoris
Sherry, L., Grehan, K., Swanson, J. J., Bahar, M. W., Porta, C., Fry, E. E., Stuart, D. I., Rowlands, D. J., & Stonehouse, N. J. (2022) · doi:10.1101/2022.09.16.508282 · Cited by 18
Wyatt, H. V. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.3.547 · Cited by 17 · cited 4×
“In some cases, the virus can reach the CNS by crossing the blood–brain barrier via infected mononuclear cells [28].”
BackgroundInfluentialYao, N., Liu, Y., Xu, J.-W., Wang, Q., Yin, Z.-D., Wen, N., Yang, H., Rodewald, L. E., & Zhang, Z.-Y. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7136a2 · Cited by 16 · cited 3×
“In a study, the efficacy of the inactivated Sabin strain vaccine (sIPV) was evaluated in response to an outbreak of cVDPV2 in the province of Sichuan, China, from 2019 to 2021.”
BackgroundInfluentialProduction and Characterisation of Stabilised PV-3 Virus-like Particles Using Pichia pastoris
Sherry, L., Grehan, K., Swanson, J. J., Bahar, M. W., Porta, C., Fry, E. E., Stuart, D. I., Rowlands, D. J., & Stonehouse, N. J. (2022) · Viruses · doi:10.3390/v14102159 · Cited by 16
Update on Wild Poliovirus Type 1 Outbreak-Southeastern Africa, 2021–2022
Davlantes, E., Greene, S. A., Tobolowsky, F. A., Biya, O., Wiesen, E., Abebe, F., Weldetsadik, M. B., Eboh, V. A., Chisema, M. N., da Conceição Mário, B., et al. (2023) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7215a3 · Cited by 16 · cited 3×
“In 2022, 2 cases of WPV1 were reported in Afghanistan, 20 in Pakistan and 8 cases in Mozambique (non-endemic country) (Figure 2b) [6].”
BackgroundBermingham, W. H., Canning, B., Wilton, T., Kidd, M., Klapsa, D., Majumdar, M., Sooriyakumar, K., Martin, J., & Huissoon, A. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1135834 · Cited by 15
Kitamura, K., & Shimizu, H. (2021) · Viruses · doi:10.3390/v13071407 · Cited by 14 · cited 7×
“Less than 1% of polio cases result in temporary or permanent acute flaccid paralysis (AFP) [22].”
BackgroundInfluentialGlobal update on vaccine-derived polioviruses, January 2006-August 2007.
(2007) · PubMed · Cited by 14
Bickerstaffe, A., Beelen, A., Lutter, R., & Nollet, F. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.10.019 · Cited by 13 · cited 1×
“In addition, levels of TNF-α and IFN-γ have been observed in the serum and cerebrospinal fluid of PPS patients [40,41].”
BackgroundYang, H., Qi, Q., Zhang, Y., Wen, N., Cao, L., Liu, Y., Fan, C., Yan, D., Zhu, X., Hao, L., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.49710 · Cited by 13
Delpeyroux, F., Colbère-Garapin, F., Razafindratsimandresy, R., Sadeuh-Mba, S., Joffret, M.-L., Rousset, D., & Blondel, B. (2013) · médecine/sciences · doi:10.1051/medsci/20132911021 · Cited by 11 · cited 1×
“These cVDPVs have acquired the important biological properties of the WPV, namely efficient transmission from person to person and the ability to cause severe paralysis [90].”
BackgroundThe Long and Winding Road to Eradicate Vaccine-Related Polioviruses
Cochi, S. L., & Pallansch, M. A. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa393 · Cited by 9
Vaccine-derived polioviruses--update.
(2006) · PubMed · Cited by 8
Pathological Analysis of Spinal Cords from Survivors of Poliomyelitis
Kaminski, H. J., Tresser, N. J., Hogan, R. E., et al. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb27569.x · Cited by 6 · cited 1×
“Indeed, inflammatory changes in the spinal cord have been observed postmortem in PPS patients [38,39].”
BackgroundPoliovirus et entérovirus C, même espèce, même « tribu » virale
Andrianarivelo, M. R., Jégouic, S., Bessaud, M., & Delpeyroux, F. (2008) · médecine/sciences · doi:10.1051/medsci/2008245452 · Cited by 6
(2008) · PubMed · Cited by 4
nouveau vaccin antipoliomyélitique oral : un tournant décisif pour le programme d’éradication ?
Bessaud, M. (2021) · Médecine tropicale et santé internationale · doi:10.48327/mtsi.2021.191 · Cited by 4
Wood (1999) · doi:10.1002/(sici)1096-9071(199906)58:2<188::aid-jmv15>3.0.co;2-h
Research works printed but not linked: 1
- Knipe, D.M., and Howley, P.M. (2007). Fields Virology, Lippincott Williams and Wilkins.
Cited by
The Glucans Mushrooms: Molecules of Significant Biological and Medicinal Value
Flores, G. A., Cusumano, G., Venanzoni, R., & Angelini, P. (2024) · Polysaccharides · doi:10.3390/polysaccharides5030016 · Cited by 47
“This antiviral action is believed to involve increased interferon-gamma release and enhanced PBMC proliferation [75,76].”
Chatterjee, S., Kordbacheh, R., & Sin, J. (2024) · Microorganisms · doi:10.3390/microorganisms12020274 · Cited by 26
Structural Virology: The Key Determinants in Development of Antiviral Therapeutics
Handa, T., Saha, A., Narayanan, A., Ronzier, E., Kumar, P., Singla, J., & Tomar, S. (2025) · Viruses · doi:10.3390/v17030417 · Cited by 18
“…Orthomyxoviridae (e.g., influenza viruses) [17,18], Herpesviridae (e.g., herpes simplex virus-HSV) [22–25], Papillomaviridae (e.g., human papillomavirus-HPV) [26–28], Retroviridae (e.g., human immunodeficiency virus-HIV-1 and HIV-2) [29,30], and Picornaviridae (e.g., poliovirus) families [31,32].”
Eze, O. V., Meyer, J. C., & Campbell, S. (2025) · Vaccines · doi:10.3390/vaccines13030232 · Cited by 20
“The infection was linked to the type 2 variant detected earlier in environmental samples collected from Gaza wastewater, with poor sanitation resulting in poliovirus typically spreading through the fecal–oral route in unsanitary environments [15,23,24].”
Enterovirus Antibodies: Friends and Foes
Mbani, C. J., Morvan, C., Nekoua, M. P., Debuysschere, C., Alidjinou, E. K., Moukassa, D., & Hober, D. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.70004 · Cited by 9
“In recent years, native antigenic PV VLPs have been produced using various systems such as mammalian cells, plants, insects, bacteria, and yeast [83].”
InfluentialSelf-citation
Metadata
- Authors
- Mbani, C. J., Nekoua, M. P., Moukassa, D., & Hober, D.
- Affiliations
- Université de Lille (FR)
- Marien Ngouabi University (CG)
- Corresponding author
- Hober, Didier
- Venue
- Microorganisms
- Publisher
- MDPI AG
- Published
- 2023-05-17
- Volume
- 11
- Issue
- 5
- Pages
- 1323
- ISSN
- 2076-2607 (ISSN-L)
- PMC
- PMC10220725
- OpenAlex
- W4377103213
- Cited by
- 34
- References
- 137
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 15 · 2023: 1
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Microorganisms (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, cc-by)
- Funders
- Ministère de l’Education Nationale de la Recherche et de la Technologie (ULR3610, 130771P)
- “SSHN JEUNE CHERCHEUR” scholarship of Ministère de l’Europe et des Affaires Etrangères and by Campus France (ULR3610, 130771P)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- poliovirus, wild poliovirus type 1, vaccine-derived poliovirus, oral polio vaccine, inactivated poliovirus vaccine, bivalent oral poliovirus vaccine, virus-like particle vaccine, polio eradication, paralytic poliomyelitis, Global Polio Eradication Initiative
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.